These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9883063)

  • 21. [New approaches in the treatment of hypertension in metabolic diseases].
    Rosolová H
    Cas Lek Cesk; 1998 Jun; 137(12):372-7. PubMed ID: 9721474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hypertension in patients with diabetes mellitus--selected pathogenetic and therapeutic aspects].
    Zukowska-Szczechowska E; Tomaszewski M; Grzeszczak W
    Przegl Lek; 2001; 58(3):124-6. PubMed ID: 11475857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure, diabetes and diabetic nephropathy.
    Chantrel F; Moulin B; Hannedouche T
    Diabetes Metab; 2000 Jul; 26 Suppl 4():37-44. PubMed ID: 10922972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin resistance and hypertension. Patients in double jeopardy for cardiovascular disease.
    McLaughlin T; Reaven G
    Geriatrics; 2000 Jun; 55(6):28-32, 35. PubMed ID: 10872343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M
    Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases.
    Cersosimo E; DeFronzo RA
    Diabetes Metab Res Rev; 2006; 22(6):423-36. PubMed ID: 16506274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.
    Suskin N; McKelvie RS; Burns RJ; Latini R; Pericak D; Probstfield J; Rouleau JL; Sigouin C; Solymoss CB; Tsuyuki R; White M; Yusuf S
    Eur Heart J; 2000 Aug; 21(16):1368-75. PubMed ID: 10952826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes.
    Frontoni S; Bracaglia D; Gigli F
    Nutr Metab Cardiovasc Dis; 2005 Dec; 15(6):441-9. PubMed ID: 16314230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetic hypertensive patients. Is this a group in need of particular care and attention?
    Parving HH
    Diabetes Care; 1999 Mar; 22 Suppl 2():B76-9. PubMed ID: 10097904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.
    Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE
    J Nephrol; 2008; 21(4):566-9. PubMed ID: 18651547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
    Ribeiro AB
    Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The crosstalk between insulin and the sympathetic nervous system: possible implications in the pathogenesis of essential hypertension.
    Lembo G; Vecchione C; Iaccarino G; Trimarco B
    Blood Press Suppl; 1996; 1():38-42. PubMed ID: 9162436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension and renal complications in type 2 diabetes.
    Nosadini R
    Semin Vasc Med; 2002 Feb; 2(1):109-19. PubMed ID: 16222601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microalbuminuria in essential hypertension.
    Crippa G
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S74-7. PubMed ID: 11986900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin resistance and essential hypertension: mechanisms and clinical implications.
    Morris AD; Connell JM
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S47-52. PubMed ID: 8141165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.